Equities analysts expect Aratana Therapeutics Inc (NASDAQ:PETX) to post earnings per share (EPS) of ($0.13) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Aratana Therapeutics’ earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.11). Aratana Therapeutics posted earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 38.1%. The company is scheduled to report its next quarterly earnings results on Thursday, November 1st.

On average, analysts expect that Aratana Therapeutics will report full-year earnings of ($0.48) per share for the current fiscal year, with EPS estimates ranging from ($0.61) to ($0.29). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.30) to ($0.14). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Aratana Therapeutics had a negative net margin of 154.23% and a negative return on equity of 35.25%. The firm had revenue of $4.91 million during the quarter, compared to analyst estimates of $4.72 million.

A number of analysts have recently commented on the stock. Zacks Investment Research lowered shares of Aratana Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub lowered shares of Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 2nd. ValuEngine upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. Finally, Stifel Nicolaus reduced their price target on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, August 6th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $7.96.

Shares of PETX stock opened at $5.28 on Wednesday. Aratana Therapeutics has a 52 week low of $3.67 and a 52 week high of $7.28. The company has a market capitalization of $278.40 million, a PE ratio of -5.44 and a beta of 2.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.02 and a quick ratio of 2.44.

In related news, insider Ernst Heinen sold 10,372 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $5.15, for a total transaction of $53,415.80. Following the completion of the sale, the insider now directly owns 157,406 shares in the company, valued at $810,640.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter Steven St sold 11,513 shares of the business’s stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $4.33, for a total transaction of $49,851.29. Following the sale, the insider now owns 649,233 shares of the company’s stock, valued at $2,811,178.89. The disclosure for this sale can be found here. Insiders have sold 104,187 shares of company stock valued at $595,372 over the last 90 days. 5.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in PETX. American Century Companies Inc. bought a new stake in Aratana Therapeutics during the second quarter valued at approximately $195,000. Bank of Montreal Can grew its position in Aratana Therapeutics by 152.9% during the third quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 31,053 shares during the period. Jane Street Group LLC grew its position in Aratana Therapeutics by 683.0% during the first quarter. Jane Street Group LLC now owns 81,952 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 71,486 shares during the period. Schwab Charles Investment Management Inc. grew its position in Aratana Therapeutics by 23.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after buying an additional 17,300 shares during the period. Finally, Citadel Advisors LLC grew its position in Aratana Therapeutics by 42.3% during the first quarter. Citadel Advisors LLC now owns 97,819 shares of the biopharmaceutical company’s stock valued at $432,000 after buying an additional 29,061 shares during the period. Institutional investors own 65.44% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Read More: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.